Neuroscience
New Research Identifies SOX6 Protein as Potential Key to Myelin Repair in Multiple Sclerosis
Groundbreaking research published in Cell reveals that targeting the SOX6 protein could enable myelin repair in multiple sclerosis patients, potentially opening new therapeutic avenues for the neurodegenerative disease.
Cybin Inc. to Present at H.C. Wainwright Global Investment Conference
Cybin Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference, highlighting its late-stage neuropsychiatry developments including breakthrough therapy-designated treatments for major depressive disorder and generalized anxiety disorder.
Cybin Inc. to Present at Cantor Global Healthcare Conference, Highlighting Progress in Neuropsychiatric Treatments
Cybin Inc.'s participation in the Cantor Global Healthcare Conference underscores the company's advancing clinical programs for mental health disorders, including its Phase 3 CYB003 for major depressive disorder and Phase 2 CYB004 for generalized anxiety disorder, both of which hold significant potential to address unmet medical needs.
Annovis Bio CEO to Present at H.C. Wainwright Global Investment Conference
Annovis Bio's CEO will present at the H.C. Wainwright conference, highlighting the company's focus on developing innovative therapies for neurodegenerative diseases like Alzheimer's and Parkinson's.
Clene Inc. Advances Neurodegenerative Disease Treatment CNM-Au8® Toward Potential FDA Accelerated Approval
Clene Inc. is progressing its oral treatment CNM-Au8® for ALS and multiple sclerosis through late-stage clinical development, with key FDA meetings and regulatory catalysts potentially accelerating commercialization for patients with limited treatment options.
MyBioSource Launches Validated Anti-CALB2 Antibody for Neuroscience Research
MyBioSource has introduced a validated sheep anti-rat calretinin polyclonal antibody that enables advanced research into calcium signaling, neuroprotection, and neurodegeneration across multiple species.
Cybin Receives Australian Approval for Phase 3 Study of Psychedelic-Based Depression Treatment
Cybin Inc. has secured Australian regulatory approval to conduct its EMBRACE Phase 3 clinical trial of CYB003, a novel deuterated psilocin analog, marking a significant advancement in developing next-generation treatments for major depressive disorder.
NRx Pharmaceuticals' Depression Treatment Receives FDA Fast Track Designation
NRx Pharmaceuticals' NRX-100 received FDA Fast Track designation for treating suicidal ideation, potentially expanding its market to 13 million U.S. adults and offering a novel approach targeting neuroplasticity in depression treatment.
New Podcast Explores Neuroplastic Pain Affecting 1.5 Billion People Worldwide
Dr. David Clarke's podcast 'The Story Behind the Symptoms' addresses the growing epidemic of neuroplastic pain conditions through patient interviews and evidence-based Neuroplastic Recovery Therapy, offering alternatives to traditional medical treatments.
AI-Human Collaboration Pioneers Emotional Brain Shunting Research
A groundbreaking collaboration between human researchers and AI systems from OpenAI and Google DeepMind is developing the Emotional Brain Shunting framework to study how the brain redirects emotional energy, potentially revolutionizing mental health and resilience science.
Everyday Strategies to Enhance Brain Health and Cognitive Function
Exploring simple, effective methods to maintain and improve brain health through mental stimulation, diet, mental wellness, and physical activity.
Clene Inc. to Share Corporate Update at Emerging Growth Conference
Clene Inc. is set to present a corporate update at the Emerging Growth Conference, highlighting its progress in developing treatments for neurodegenerative diseases.
Cybin Inc. Receives EU Approval for Phase 3 MDD Study, Marking a Significant Step in Mental Health Treatment
Cybin Inc. has secured European approval to commence its EMBRACE Phase 3 study for CYB003, a potential breakthrough in treating Major Depressive Disorder, highlighting a pivotal moment in neuropsychiatry.
Clene Inc. to Showcase Neurodegenerative Disease Treatments at Canaccord 45th Annual Growth Conference
Clene Inc. will present its innovative treatments for neurodegenerative diseases at the Canaccord 45th Annual Growth Conference, highlighting potential advancements in ALS and MS therapy.
BTT Brain Wellness Institute Pioneers Non-Invasive Brain Health Solutions
The BTT Brain Wellness Institute, founded by Dr. M. Marc Abreu, introduces innovative, non-invasive treatments to optimize brain function, marking a significant advancement in personalized brain health care.
Clene Inc. Advances Toward FDA Approval for ALS Treatment, Highlighting Market Potential
Clene Inc. is making significant progress toward FDA accelerated approval for its ALS drug CNM-Au8®, targeting a $1.3 billion market by 2034 with a novel approach to neurodegenerative diseases.
University of Sydney Researchers Discover Potential Breakthrough in Parkinson's Treatment
A preclinical study by University of Sydney researchers has successfully reversed Parkinson's-like symptoms in mice by targeting a malfunctioning protein, offering hope for future human treatments.
NeuroEyeCoach Study Highlights Benefits for Vision Rehabilitation in Home and Clinic Settings
A new study on NovaVision's NeuroEyeCoach demonstrates significant improvements in visual search performance for patients, whether used at home or in a clinic, supporting its role in vision rehabilitation.
Oragenics Inc. Raises $16.5 Million to Advance Intranasal Concussion Therapy
Oragenics Inc. has successfully closed a $16.5 million public offering to fund the development of its intranasal therapy for concussions, marking a significant step forward in neurological disorder treatments.
InFlectis BioScience's IFB-088 Shows Promise in ALS Treatment Through Groundbreaking Study
InFlectis BioScience's study on IFB-088 demonstrates potential in addressing TDP-43 proteinopathy, offering hope for ALS patients by improving motor neuron survival and function.
Creative Biolabs Enhances Neuroscience Research with Cutting-Edge Electrophysiology and Electrode Chip Technologies
Creative Biolabs introduces advanced electrophysiology and electrode chip technologies to significantly impact neuroscience research, offering new avenues for understanding neuronal activity and developing neurotherapeutics.
InMed Pharmaceuticals Reports Promising Preclinical Results for Alzheimer's Treatment
InMed Pharmaceuticals Inc. announces positive preclinical results for INM-901, showing potential in reducing neuroinflammation associated with Alzheimer's disease, independent of amyloid beta or tau pathology.
Cure Alzheimer’s Fund Honors Breakthrough Research with Jeffrey L. Morby Prize
The Cure Alzheimer’s Fund has awarded the Jeffrey L. Morby Prize to researchers Andrew S. Yoo and Zhao Sun for their innovative study on modeling late-onset Alzheimer’s disease, marking a significant step forward in understanding and potentially treating the condition.
Brisa Therapeutics Highlights Nature's Impact on Mental Wellness in Podcast Feature
Brisa Therapeutics discusses the therapeutic benefits of nature on mental and emotional health in a recent podcast episode, emphasizing the science behind how natural environments facilitate healing and nervous system regulation.
Clene Inc. CEO to Present at Investor Summit Virtual, Highlighting Progress in Neurodegenerative Disease Treatment
Clene Inc.'s CEO Rob Etherington will update investors on the company's advancements in treating neurodegenerative diseases at the Investor Summit Virtual, showcasing potential breakthroughs in mitochondrial health and neuronal protection.
Cure Alzheimer’s Fund Strengthens Leadership with New Board Appointments
Cure Alzheimer’s Fund enhances its leadership team by appointing Christine Villas-Boas and Brittany Bowlen to its Board of Directors, aiming to accelerate research against Alzheimer’s disease.
Neuroscientists Develop RADICAL: A Breakthrough Tool for Precise Neural Control
Researchers have engineered a novel chemogenetic tool called RADICAL that enables non-invasive, precise manipulation of brain activity using a synthetic chemical, offering significant potential for neuroscience research and therapeutic interventions.
Swedish Study Reveals Potential Neurological Connection Between Autism and Parkinson's Disease
A groundbreaking research from Karolinska Institutet suggests a significant biological link between autism spectrum disorder and Parkinson's disease, potentially opening new avenues for understanding neurodegenerative conditions.
Creative Biolabs to Explore Neural Mechanisms of Survival Behaviors in Upcoming Webinar
A pioneering webinar hosted by Creative Biolabs will delve into the complex neural circuits that govern fundamental survival behaviors, offering researchers insights into how organisms perceive danger and make critical decisions.
Annovis Bio Advances Alzheimer's Treatment with Phase 3 Clinical Trial
Annovis Bio has initiated a pivotal Phase 3 clinical trial for buntanetap, a potential treatment for early Alzheimer's disease, with the potential to address symptomatic and disease-modifying aspects of the condition.